Nanotherapeutics for Alzheimer’s disease (AD): Past, present and future

References

• Aggarwal BB, Harikumar KB. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 41, 40–59.
   PubMed Web of Science ®Google Scholar
• Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. (2008). Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer’s disease and cerebral amyloid angiopathy. Pharm Res, 25, 2674–2684.
   PubMed Web of Science ®Google Scholar
• Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. (2010). Strategy for effective brain drug delivery. Eur J Pharm Sci, 40, 385–403.
   PubMed Web of Science ®Google Scholar
• Alvarez A, Alarcón R, Opazo C, Campos EO, Muñoz FJ, Calderón FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC. (1998). Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci, 18, 3213–3223.
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. (1998). Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul, 15, 67–74.
   PubMed Web of Science ®Google Scholar
• Amtul Z, Wang L, Westaway D, Rozmahel RF. (2010). Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer’s disease. Neuroscience, 169, 781–786.
   PubMed Web of Science ®Google Scholar
• Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB. (2010). Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol, 79, 330–338.
   PubMed Web of Science ®Google Scholar
• Andrews DF. (1991). Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet, 337, 1304–1308.
   PubMed Web of Science ®Google Scholar
• Anekonda TS. (2006). Resveratrol—a boon for treating Alzheimer’s disease?. Brain Res Rev, 52, 316–326.
   PubMed Web of Science ®Google Scholar
• Banks WA. (2008). The Blood Brain Barrier. . In: Tsuneya, I, Howard, EG. (eds.), Neuroimmune Pharmacology. Springer, pp. 21–38.
   Google Scholar
• Barbu E, Molnàr E, Tsibouklis J, Górecki DC. (2009). The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv, 6, 553–565.
   PubMed Web of Science ®Google Scholar
• Barrenetxe J, Delagrange P, Martínez JA. (2004). Physiological and metabolic functions of melatonin. J Physiol Biochem, 60, 61–72.
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. (2004). Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci, 1012, 224–236.
   PubMed Web of Science ®Google Scholar
• Bastus NG, Kogan MJ, Amigo R, Grillo-Bosch D, Araya E, Turiel A, Labarta A, Giralt E, Puntes VF. (2007). Gold nanoparticles for selective and remote heating of beta-amyloid protein aggregates. Mater Sci Eng: C, 27, 1236–40.
   Google Scholar
• BAUA. Nanotechnology: Health and environmental risks of nanoparticles - Research strategy: Bundesanstalt fur arbeitsschutz und arbeitmedizin (Baua), Germany, 2006.
   Google Scholar
• Baum L, Ng A. (2004). Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis, 6, 367–77; discussion 443.
   PubMed Web of Science ®Google Scholar
• Bilati U, Allémann E, Doelker E. (2005). Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci, 24, 67–75.
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. (2009). Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev, CD001191.
   Google Scholar
• Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. (2002). Iron: a pathological mediator of Alzheimer disease? Dev Neurosci, 24, 184–187.
   PubMed Web of Science ®Google Scholar
• Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JM, Rowley D, Halliwell B, Cornish A. (1985). Cerebral and ocular toxicity induced by desferrioxamine. Q J Med, 56, 345–355.
   PubMedGoogle Scholar
• Bondy SC, Guo-Ross SX, Truong AT. (1998). Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res, 799, 91–96.
   PubMed Web of Science ®Google Scholar
• Borm PJ, Kreyling W. (2004). Toxicological hazards of inhaled nanoparticles–potential implications for drug delivery. J Nanosci Nanotechnol, 4, 521–531.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Audinot V, Ferry G, Delagrange P. (2005). Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci, 26, 412–419.
   PubMed Web of Science ®Google Scholar
• Brem H, Walter KA, Tamargo RJ, Olivi A, Langer R. (1994). Drug delivery to the brain. In: Domb AJ, ed. Polymeric Site-Specific Pharmacotherapy. New York: John Wiley & Sons, 117–139.
   Google Scholar
• Butt AM, Jones HC, Abbott NJ. (1990). Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol (Lond), 429, 47–62.
   Google Scholar
• Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci, 4, 233–234.
   PubMed Web of Science ®Google Scholar
• Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G. (2004). Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis, 6, 165–169.
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, Zhu X. (2007). Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res, 32, 1640–1645.
   PubMed Web of Science ®Google Scholar
• Castelluccio C, Bolwell GP, Gerrish C, Rice-Evans C. (1996). Differential distribution of ferulic acid to the major plasma constituents in relation to its potential as an antioxidant. Biochem J, 316 (Pt 2), 691–694.
   PubMedGoogle Scholar
• Chakraborty C, Sarkar B, Hsu CH, Wen ZH, Lin CS, Shieh PC. (2009). Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol, 93, 285–286.
   PubMed Web of Science ®Google Scholar
• Chen D, Xi T, Bai J. (2007). Biological effects induced by nanosilver particles: in vivo study. Biomed Mater, 2, S126–S128.
   PubMed Web of Science ®Google Scholar
• Chen J, Patil S, Seal S, McGinnis JF. (2006). Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol, 1, 142–150.
   PubMed Web of Science ®Google Scholar
• Corrigan OI, Li X. (2009). Quantifying drug release from PLGA nanoparticulates. Eur J Pharm Sci, 37, 477–485.
   PubMed Web of Science ®Google Scholar
• Coyle J, Kershaw P. (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease. Biol Psychiatry, 49, 289–299.
   PubMed Web of Science ®Google Scholar
• Craparo EF, Pitarresi G, Bondì ML, Casaletto MP, Licciardi M, Giammona G. (2008). A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci, 8, 247–259.
   PubMed Web of Science ®Google Scholar
• Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF. (1991). Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet, 337, 1304–1308.
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Barnham KJ, Bush AI, White AR. (2006). Therapeutic treatments for Alzheimer’s disease based on metal bioavailability. Drug News Perspect, 19, 469–474.
   PubMed Web of Science ®Google Scholar
• Crowe A, Morgan EH. (1994). Effects of chelators on iron uptake and release by the brain in the rat. Neurochem Res, 19, 71–76.
   PubMed Web of Science ®Google Scholar
• Cuajungco MP, Fagét KY, Huang X, Tanzi RE, Bush AI. (2000). Metal chelation as a potential therapy for Alzheimer’s disease. Ann N Y Acad Sci, 920, 292–304.
   PubMed Web of Science ®Google Scholar
• Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, Mumper RJ. (2005). Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm, 59, 263–272.
   PubMed Web of Science ®Google Scholar
• Davson H, Segal MB. (1996). Physiology of the CSF and Blood– Brain Barriers. Boca Raton, Florida: CRC Press.
   Google Scholar
• Dunne M, Corrigan I, Ramtoola Z. (2000). Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 21, 1659–1668.
   PubMed Web of Science ®Google Scholar
• Epstein FH. (1997). Mechanisms of disease− melatonin in humans. N Engl J Med, 336, 186–195.
   PubMed Web of Science ®Google Scholar
• Faraji AH, Wipf P. (2009). Nanoparticles in cellular drug delivery. Bioorg Med Chem, 17, 2950–2962.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Miller ML, Pejovic V. (2008). Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord, 25, 408–422.
   PubMed Web of Science ®Google Scholar
• Farlow MR. (2001). Pharmacokinetic profiles of current therapies for Alzheimer’s disease: implications for switching to galantamine. Clin Ther, 23 Suppl A, A13–A24.
   PubMed Web of Science ®Google Scholar
• Feng S, Huang G. (2001). Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release, 71, 53–69.
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer’s Disease International. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112–2117.
   PubMed Web of Science ®Google Scholar
• Florence AT, Hillery AM, Hussain N, Jani PU. (1995). Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target, 3, 65–70.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Simões S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release, 83, 273–286.
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, Wilcock GK. (1999). The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatr, 66, 137–147.
   PubMed Web of Science ®Google Scholar
• Gabor F, Ertl B, Wirth M, Mallinger R. (1999). Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: influence of manufacturing parameters and type of polymer on the release characteristics. J Microencapsul, 16, 1–12.
   PubMed Web of Science ®Google Scholar
• Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, Rong Z, Chen H, Jiang X. (2007). Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release, 121, 156–167.
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. (2007). Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem, 102, 1095–1104.
   PubMed Web of Science ®Google Scholar
• Gèze A, Putaux JL, Choisnard L, Jéhan P, Wouessidjewe D. (2004). Long-term shelf stability of amphiphilic beta-cyclodextrin nanosphere suspensions monitored by dynamic light scattering and cryo-transmission electron microscopy. J Microencapsul, 21, 607–613.
   PubMed Web of Science ®Google Scholar
• Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release, 57, 171–185.
   PubMed Web of Science ®Google Scholar
• Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. (2003). From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci, 20, 315–322.
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. (1999). Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 16, 1564–1569.
   PubMed Web of Science ®Google Scholar
• Gutteridge JM. (1994). Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann N Y Acad Sci, 738, 201–213.
   PubMed Web of Science ®Google Scholar
• Halliwell B. (2001). Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging, 18, 685–716.
   PubMed Web of Science ®Google Scholar
• Hardeland R, Pandi-Perumal SR, Cardinali DP. (2006). Melatonin. Int J Biochem Cell Biol, 38, 313–316.
   PubMed Web of Science ®Google Scholar
• Härtig W, Paulke BR, Varga C, Seeger J, Harkany T, Kacza J. (2003). Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer’s disease. Neurosci Lett, 338, 174–176.
   PubMed Web of Science ®Google Scholar
• Hider RC, Epemolu O, Singh S, Porter JB. (1994). Iron chelator design. Adv Exp Med Biol, 356, 343–349.
   PubMedGoogle Scholar
• Hider RC, Hall AD. (1991). Clinically useful chelators of tripositive elements. Prog Med Chem, 28, 41–173.
   PubMedGoogle Scholar
• Huang CY, Lee YD. (2006). Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: synthesis, characterization and in vitro degradation. Int J Pharm, 325, 132–139.
   PubMedGoogle Scholar
• Jang JH, Surh YJ. (2003). Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med, 34, 1100–1110.
   PubMed Web of Science ®Google Scholar
• Joshi SA, Chavhan SS, Sawant KK. (2010). Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm, 76, 189–199.
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Mahidhara G, Kanwar RK. (2009). Recent Advances in Nanoneurology for Drug Delivery to the Brain. Curr Nanosci, 5, 441–448.
   Web of Science ®Google Scholar
• Kashiwada S. (2006). Distribution of nanoparticles in the see-through medaka (Oryzias latipes). Environ Health Perspect, 114, 1697–1702.
   PubMed Web of Science ®Google Scholar
• Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V. (2011). Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta, 1808, 352–359.
   PubMed Web of Science ®Google Scholar
• Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, Lee KH, Park SB, Lee JK, Cho MH. (2006). Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci, 89, 338–347.
   PubMed Web of Science ®Google Scholar
• Klein WL, Krafft GA, Finch CE. (2001). Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci, 24, 219–224.
   PubMed Web of Science ®Google Scholar
• Kogan MJ, Bastus NG, Amigo R, Grillo-Bosch D, Araya E, Turiel A, Labarta A, Giralt E, Puntes VF. (2006). Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett, 6, 110–115.
   PubMed Web of Science ®Google Scholar
• Kong S, Liochev S, Fridovich I. (1992). Aluminum(III) facilitates the oxidation of NADH by the superoxide anion. Free Radic Biol Med, 13, 79–81.
   PubMed Web of Science ®Google Scholar
• Koo OM, Rubinstein I, Onyuksel H. (2005). Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine, 1, 193–212.
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand JP, Muller S, Prato M, Bianco A. (2007). Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol, 2, 108–113.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Petrov VE, Kharkevich DA, Alyautdin, RN. (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant coated nanoparticles. J Control Release, 49, 81–87.
   Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 10, 317–325.
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2004). Nanoparticles as drug delivery system. In: Nalwa, HS. ed. Encyclopedia of nanoscience and nanotechnology, New York: American Scientific Publisher, 161–80.
   Google Scholar
• Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47, 65–81.
   PubMed Web of Science ®Google Scholar
• Kruck TP, Fisher EA, McLachlan DR. (1993). A predictor for side effects in patients with Alzheimer’s disease treated with deferoxamine mesylate. Clin Pharmacol Ther, 53, 30–37.
   PubMed Web of Science ®Google Scholar
• Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. (2010). Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2, 35–47.
   PubMed Web of Science ®Google Scholar
• Lademann J, Weigmann H, Rickmeyer C, Barthelmes H, Schaefer H, Mueller G, Sterry W. (1999). Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol, 12, 247–256.
   PubMedGoogle Scholar
• Lam CW, James JT, McCluskey R, Hunter RL. (2004). Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci, 77, 126–134.
   PubMed Web of Science ®Google Scholar
• Leaden P, Barrionuevo J, Catalá A. (2002). The protection of long chain polyunsaturated fatty acids by melatonin during nonenzymatic lipid peroxidation of rat liver microsomes. J Pineal Res, 32, 129–134.
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R. (2001). Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev, 53, 569–596.
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. (2002). Galantamine–a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev, 8, 159–176.
   PubMedGoogle Scholar
• Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci, 21, 8370–8377.
   PubMed Web of Science ®Google Scholar
• Liu G, Bruenger FW, Miller SC, Arif AM. (1998). Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(beta-D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration. Bioorg Med Chem Lett, 8, 3077–3080.
   PubMed Web of Science ®Google Scholar
• Liu G, Garrett MR, Men P, Zhu X, Perry G, Smith MA. (2005). Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim Biophys Acta, 1741, 246–252.
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Kenner GH, Miller SC, Bruenger FW. (2004). Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics. Nucleosides Nucleotides Nucleic Acids, 23, 599–611.
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Kudo W, Perry G, Smith MA. (2009). Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett, 455, 187–190.
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Perry G, Smith MA. (2009). Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer’s disease. J Nanoneurosci, 1, 42–55.
   PubMedGoogle Scholar
• Lockman PR, Koziara JM, Mumper RJ, Allen DD. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target, 12, 635–641.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28, 1–13.
   PubMed Web of Science ®Google Scholar
• Lu J. (2007). Effect of surface modifications on the decoration of multi-walled carbon nanotubes with ruthenium nanoparticles. Carbon, 45, 1599–1605.
   Web of Science ®Google Scholar
• Lu X, Ji C, Xu H, Li X, Ding H, Ye M, Zhu Z, Ding D, Jiang X, Ding X, Guo X. (2009). Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm, 375, 89–96.
   PubMed Web of Science ®Google Scholar
• Lynch SG, Fonseca T, Levine SM. (2000). A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol (Noisy-le-grand), 46, 865–869.
   PubMed Web of Science ®Google Scholar
• Majzik A, Fülöp L, Csapó E, Bogár F, Martinek T, Penke B, Bíró G, Dékány I. (2010). Functionalization of gold nanoparticles with amino acid, beta-amyloid peptides and fragment. Colloids Surf B Biointerfaces, 81, 235–241.
   PubMed Web of Science ®Google Scholar
• Marder K. (2002). Donepezil for cognitive impairment in Parkinson’s disease: a randomized controlled trial. Curr Neurol Neurosci Rep, 2, 390–391.
   PubMedGoogle Scholar
• Matsubara E, Shoji M, Murakami T, Kawarabayashi T, Abe K. (2003). Alzheimer’s disease and melatonin. Int Congr Ser, 1252, 395–398.
   Google Scholar
• Mistrya A, Stolnika S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm, 379, 146–157.
   Google Scholar
• Mittal G, Carswell H, Brett R, Currie S, Kumar MN. (2011). Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer’s pathology. J Control Release, 150, 220–228.
   PubMed Web of Science ®Google Scholar
• Mulik R, Mahadik K, Paradkar A. (2009). Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci, 37, 395–404.
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. (2004). Drug delivery to the brain–realization by novel drug carriers. J Nanosci Nanotechnol, 4, 471–483.
   PubMed Web of Science ®Google Scholar
• Nabeshima T, Nitta A. (1994). Memory impairment and neuronal dysfunction induced by beta-amyloid protein in rats. Tohoku J Exp Med, 174, 241–249.
   PubMed Web of Science ®Google Scholar
• Nash JM. (2001). Alzheimer’s disease. New insights into its cause lead to new drug strategies. Time, 157, 80–1, 85.
   Google Scholar
• Neeraj V, Taehong M, Rhul M, Christopher NB, Steven M, Hong D, Ken-Tye Y, Indrajit R. (2010). Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology, 8, 22.
   PubMedGoogle Scholar
• Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit D, Yang H; ILSI Research Foundation/Risk Science Institute Nanomaterial Toxicity Screening Working Group. (2005). Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol, 2, 8.
   PubMed Web of Science ®Google Scholar
• Oberdörster G, Oberdörster E, Oberdörster J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect, 113, 823–839.
   PubMed Web of Science ®Google Scholar
• Olanow CW. (1992). An introduction to the free radical hypothesis in Parkinson’s disease. Ann Neurol, 32 Suppl, S2–S9.
   PubMedGoogle Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. (2004). Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res,75, 742–750.
   PubMed Web of Science ®Google Scholar
• Pantarotto D, Briand JP, Prato M, Bianco A. (2004). Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb), 7, 16–17.
   Google Scholar
• Pardridge WM. (2003). Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv, 3, 90–105, 51.
   PubMedGoogle Scholar
• Park K. (2009). Transport across the blood–brain barrier using albumin nanoparticles. J Control Release, 137, 78–86.
   PubMedGoogle Scholar
• Pasha S, Gupta K. (2010). Various drug delivery approaches to the central nervous system. Expert Opin Drug Deliv, 7, 113–135.
   PubMed Web of Science ®Google Scholar
• Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S. (2008). Progress in drug delivery to the central nervous system by the prodrug approach. Molecules, 13, 1035–1065.
   PubMed Web of Science ®Google Scholar
• Pike CJ, Carroll JC, Rosario ER, Barron AM. (2009). Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol, 30, 239–258.
   PubMed Web of Science ®Google Scholar
• Popovic N, Brundin P. (2006). Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm, 314, 120–126.
   PubMed Web of Science ®Google Scholar
• Porter AE, Gass M, Muller K, Skepper JN, Midgley PA, Welland M. (2007). Direct imaging of single-walled carbon nanotubes in cells. Nat Nanotechnol, 2, 713–717.
   PubMed Web of Science ®Google Scholar
• Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, Hider RC. (1988). Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood, 72, 1497–1503.
   PubMed Web of Science ®Google Scholar
• Prasad KN, Hovland AR, Cole WC, Prasad KC, Nahreini P, Edwards-Prasad J, Andreatta CP. (2000). Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale. Clin Neuropharmacol, 23, 2–13.
   PubMed Web of Science ®Google Scholar
• Ramassamy C. (2006). Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol, 545, 51–64.
   PubMed Web of Science ®Google Scholar
• Rapoport SI, Ohno K, Fredericks WR, Pettigrew KD. (1978). Regional cerebrovascular permeability to [14C]sucrose after osmotic opening of the blood-brain barrier. Brain Res, 150, 653–657.
   PubMed Web of Science ®Google Scholar
• Razay G, Wilcock GK. (2008). Galantamine in Alzheimer’s disease. Expert Rev Neurother, 8, 9–17.
   PubMedGoogle Scholar
• Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. (2011). Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer’s disease. J Alzheimers Dis, 23, 61–77.
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Gambi F, Feliciani C, Salone A, Toma L, DeLuca G, Salvatore M, Conti P, Gambi D. (2004). Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol, 148, 162–171.
   PubMed Web of Science ®Google Scholar
• Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjögren M, Wallin A, Xilinas M, Gottfries CG. (2001). Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord, 12, 408–414.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Oh CS, Fujimori O. (1996). Melatonin Its intracellular and genomic actions. Trends Endocrinol Metab, 7, 22–27.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Burkhardt S. (2002). Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Ageing Dev, 123, 1007–1019.
   PubMed Web of Science ®Google Scholar
• Reiter RJ. (1998). Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol, 56, 359–384. Res Rev, 52, 316–326.
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J. (2008). Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res, 1214, 177–187.
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. (2005). Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci, 25, 8807–8814.
   PubMed Web of Science ®Google Scholar
• Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. (2005). A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res, 2, 131–136.
   PubMedGoogle Scholar
• Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60, 1685–1691.
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Masters CL. (2004). Metal-protein attenuating compounds and Alzheimer’s disease. Expert Opin Investig Drugs, 13, 1585–1592.
   PubMed Web of Science ®Google Scholar
• Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. (2011). Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Control Release, 152, 208–231.
   PubMed Web of Science ®Google Scholar
• Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. (1995). Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res, 705, 125–135.
   PubMed Web of Science ®Google Scholar
• Saraiva AM, Cardoso I, Saraiva MJ, Tauer K, Pereira MC, Coelho MA, Möhwald H, Brezesinski G. (2010). Randomization of amyloid-ß-peptide(1–42) conformation by sulfonated and sulfated nanoparticles reduces aggregation and cytotoxicity. Macromol Biosci, 10, 1152–1163.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. (2000). In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals. J Neurochem, 74, 270–279.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Smith MA, Perry G. (2001). Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem, 8, 721–738.
   PubMed Web of Science ®Google Scholar
• Schaffazick SR, Pohlmann AR, de Cordova CA, Creczynski-Pasa TB, Guterres SS. (2005). Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int J Pharm, 289, 209–213.
   PubMedGoogle Scholar
• Schaffazick SR, Siqueira IR, Badejo AS, Jornada DS, Pohlmann AR, Netto CA, Guterres SS. (2008). Incorporation in polymeric nanocapsules improves the antioxidant effect of melatonin against lipid peroxidation in mice brain and liver. Eur J Pharm Biopharm, 69, 64–71.
   PubMed Web of Science ®Google Scholar
• Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. (1998). Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci, 87, 1305–1307.
   PubMed Web of Science ®Google Scholar
• Schubert D, Chevion M. (1995). The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun, 216, 702–707.
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 285, 1569–1572.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev, 81, 741–766.
   PubMed Web of Science ®Google Scholar
• Sharma HS, Sharma A. (2007). Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog Brain Res, 162, 245–273.
   PubMed Web of Science ®Google Scholar
• Sharma HS, Johanson CE. (2007). Blood-cerebrospinal fluid barrier in hyperthermia. Prog Brain Res, 162, 459–478.
   PubMed Web of Science ®Google Scholar
• Sharma M, Gupta YK. (2002). Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci, 71, 2489–2498.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Gescher AJ, Steward WP. (2005). Curcumin: the story so far. Eur J Cancer, 41, 1955–1968.
   PubMed Web of Science ®Google Scholar
• Siegemund T, Paulke BR, Schmiedel H, Bordag N, Hoffmann A, Harkany T, Tanila H, Kacza J, Härtig W. (2006). Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J Dev Neurosci, 24, 195–201.
   PubMed Web of Science ®Google Scholar
• Skaat H, Margel S. (2009). Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field. Biochem Biophys Res Commun, 386, 645–649.
   PubMed Web of Science ®Google Scholar
• Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. (2010). Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm, 389, 207–212.
   PubMed Web of Science ®Google Scholar
• Smith MA, Casadesus G, Joseph JA, Perry G. (2002). Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med, 33, 1194–1199.
   PubMed Web of Science ®Google Scholar
• Smith MA, Sayre LM, Monnier VM, Perry G. (1995). Radical AGEing in Alzheimer’s disease. Trends Neurosci, 18, 172–176.
   PubMed Web of Science ®Google Scholar
• Smith MA. (2006). Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss! J Alzheimers Dis, 9, 305–308.
   PubMed Web of Science ®Google Scholar
• Smith QR. (1990). Advances in neurology. In: Wurtman RJ, ed. Alzheimer’s disease, New York: Raven Press, 217–22.
   Google Scholar
• Sofroniew MV, Howe CL, Mobley WC. (2001). Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci, 24, 1217–1281.
   PubMed Web of Science ®Google Scholar
• Songjiang Z, Lixiang W. (2009). Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech, 10, 900–905.
   PubMed Web of Science ®Google Scholar
• Sun M, Gao Y, Guo C, Cao F, Song Z, Xi Y, et al. (2010). Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res, 12, 3111–3122.
   Web of Science ®Google Scholar
• Sun ML, Cheng RM, Xu XC, Chen YW, Li MG. (2006). Studies on adsorption of phenol and substituted phenols on carbon nanotubes. Chem Res Appl, 18, 13–16.
   Google Scholar
• Sun W, Xie C, Wang H, Hu Y. (2004). Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials, 25, 3065–3071.
   PubMed Web of Science ®Google Scholar
• Takenaka S, Arike T, Nakagawa K, Matsune H, Kishida M, Tanabe E. (2008). Synthesis of carbon nanotube-supported Pt nanoparticles covered with silica layers. Carbon, 46, 365–368.
   Web of Science ®Google Scholar
• Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. (2008). Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem, 104, 683–695.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y. (2007). Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion, 7, 399–401.
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mansoor MA. (2009). Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv, 6, 211–225.
   PubMed Web of Science ®Google Scholar
• Vinogradov SV, Bronich TK, Kabanov AV. (2002). Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev, 54, 135–147.
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70, 735–740.
   PubMed Web of Science ®Google Scholar
• Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. (2004). Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci, 77, 117–125.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res, 1200, 159–168.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. (2008). Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 70, 75–84.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B. (2010). Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine, 6, 144–152.
   PubMed Web of Science ®Google Scholar
• Wong SS. (1991). Chemistry of Protein Conjugation and Cross-Linking, Florida, New York: CRC Press.
   Google Scholar
• Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P. (1995). Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med, 1, 693–699.
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem, 280, 5892–5901.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhang Y, Yang Y, Sun L, Han D, Li H, Wang C. (2010). Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine, 6, 427–441.
   PubMed Web of Science ®Google Scholar
• Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol, 61, 82–88.
   PubMed Web of Science ®Google Scholar
• Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. (2004). Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci, 5, 863–873.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yokel RA. (2005). The chemical species of aluminum influences its paracellular flux across and uptake into Caco-2 cells, a model of gastrointestinal absorption. Toxicol Sci, 87, 15–26.
   PubMed Web of Science ®Google Scholar